Health Canada has approved a second generic version of the diabetes drug Ozempic, marking the first such product produced by a Canadian pharmaceutical company.
The semaglutide injection submitted by Canadian drugmaker Apotex was authorized after a review found it met federal safety, efficacy, and quality standards, according to a Health Canada news release. The generic drug will be administered as a once-weekly injection, consistent with existing semaglutide treatments.
Toronto-based Apotex focuses on generic medicines and operates manufacturing facilities in Canada, the United States, Mexico, and India. The company says it produces about 25 billion doses annually and exports to more than 115 countries….